PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to present its Q1 Interim Financial Statement for the period ending November 30, 2023.
Related news for (MDXXF)
- PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
- PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
- PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
- PharmAla Closes Private Placement and Concurrent Debt Settlement
- PharmAla Announces Private Placement and Concurrent Debt Settlement